Royalty Report: Medical, Cell Line, Drugs – Collection: 286075

$100.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 4

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 4

Primary Industries

  • Medical
  • Cell Line
  • Drugs
  • Supply
  • Biotechnology

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 286075

License Grant
Licensor, government research agency, grants to Licensee, subject to the terms and conditions herein, an exclusive license in the Licensed Territory under the Licensed Patents to make, have made, use, have used, sell and have sold Licensed Products for the term of this Agreement.

Licensor grants to Licensee, subject to the terms and conditions herein, an exclusive license in the Licensed Territory to make, have made, use, have used, sell and have sold Licensed Materials for the term of this Agreement.

Licensor grants to Licensee the right to grant sublicenses subject to the provisions of this Agreement and to the prior submission to and approval by Licensor of the proposed sublicense, which approval shall not be unreasonably withheld.

License Property
Licensed Patents means U.S. Patent No. 5,532,156, entitled “Hepatocyte Cell Line Derived From the Epiblast of Pig Blastocysts”, which issued on July 2, 1996, all reissues, reexaminations, and patent term extensions of this patent; U.S. Patent No. 5,866,420, entitled “Artificial Liver Device”, which issued on February 2, 1999, all reissues, reexaminations and patent term extensions of this patent; and any U.S. Patent Applications and resulting issued patents encompassed by ARS Invention Disclosure Docket No. 0024.05 entitled 'ARS-PICM-19H Fetal Pig Hepatocyte Cell Line', all continuations, divisions, reissues, reexaminations, patent term extensions of such patents, any continuations-in-part that have complied with the requirements set forth in 37 CFR 404.7 and any foreign equivalents thereof.

5,532,156 – Hepatocyte cell line derived from the epiblast of pig blastocysts
5,866,420 – Artificial liver device

Licensed Products I means any and all in vitro toxicological testing platforms for determining the potential toxicity and metabolism of new pharmacological compounds in the liver using the Licensed Materials and/or the isolated cell line of normal pluripotent parenchymal hepatocytes derived from a primary culture of pig epiblast cells as encompassed by the claims of the Licensed Patents.

Licensed Products II means any bioartifical liver device for use in human patients as encompassed by the claims of the Licensed Patents or which directly incorporates the Licensed Materials.

Licensed Materials means any and all of the fetal pig hepatocyte cell line(s) described in the Licensed Patents, including, but not limited to “ARS-PICM-19” and “ARS-PICM-19H”, and all progeny, subclones and modified and/ or unmodified derivatives thereof.

Field of Use
The license agreement is for the liver cell line for the use of patented liver cell lines in artificial liver devices

IPSCIO Record ID: 26667

License Grant
We acquired the Exclusive worldwide rights to US Patent # 6129911, for Liver Stem Cells from Licensor, a non-profit  hospital.  The invention provides a primary liver stem cell and a cell doublet consisting of a hepatocyte and the stem cell, both of which are derived from normal liver tissue. Methods of isolating the cells, genetically altering the cells, and using the cells for transplantation are also within the invention.  This patent contains twenty-four claims to a method of obtaining a population of liver cell clusters from adult stem cells and is an important enhancement to the Company's adult stem cell portfolio.
License Property
The invention provides a primary liver stem cell and a cell doublet consisting of a hepatocyte and the stem cell, both of which are derived from normal liver tissue. Methods of isolating the cells, genetically altering the cells, and using the cells for transplantation are also within the invention.  This patent contains twenty-four claims to a method of obtaining a population of liver cell clusters from adult stem cells and is an important enhancement to the Company's adult stem cell portfolio.  (The Company has an exclusive, long-term license agreement for use of the following patents owned by the hospital related to liver cell lines and Liver Assist Devices (LADs):  US Patent #6,017,760, Isolation and Culture of Porcine Hepatocytes, expires October 9, 2015;  US Patent #6,107,043, Immortalized Hepatocytes, expires February 8, 2019;  US Patent #5,043,260, Perfusion Device for Hepatocytes, expires August 27, 2008;  US Patent #4,795,459, Implantable Prosthetic Device (Endothelial), expires January 3, 2006;  US Patent #6,129,911, Liver Stem Cell, expires October 10, 2017;  US Patent #6,858,146, Artificial Liver Apparatus and Method (Sybiol), expires on February 20, 2019; and  US Patent #6,872,389, Liver Stem Cell, expires on July 8, 2019.)

IPSCIO Record ID: 291121

License Grant
University grants to Licensee a worldwide, exclusive license with the right by Licensee to grant sublicenses, under the Patent Rights to make, have made, use, sell, offer for sale and import Licensed Products. Licensee will not grant any sublicense under Patent Rights unless it first receives the prior written consent of  University, which consent will not be unreasonably withheld. University shall retain the right to make and use Licensed Products in its own laboratories for scientific purposes and for continued research  provided that such Licensed Products are not sold by University.
License Property
University is the owner of U.S. and foreign patent applications relating to (l) the proliferation of hepatocyte precursors and (2) hepatoblasts and methods of isolating same.

Patent Rights means the United States and foreign patent applications, including any divisionals, continuations and continuations-in-part, and any patents issuing thereon, including any substitutions, extensions, reissues, reexaminations, and inventors certificates.

Licensed Product means any product, the manufacture, use or sale of which is covered by a claim of Patent Rights.

Field of Use
Patents relates to research conducted on liver stem and precursor cells.  A hepatocyte is a cell of the main parenchymal tissue of the liver.

IPSCIO Record ID: 289180

License Grant
Licensor, a medical college, hereby grants to Licensee and its Affiliates a worldwide exclusive license of Licensors entire interest under Licensed Patent Rights, Licensed Know-how and Licensed Materials to make, have made, use and sell (including to sell for resale by others) Licensed Product(s).

Licensor hereby grants to Licensee under Licensed Patent Rights, Licensed Know-how and Licensed Materials the exclusive right to grant one or more non-exclusive sub-licenses to make, have made, use and sell Licensed Product(s) provided only that such sub-licenses are granted by Licensee to such sub-licensees on terms no less favorable to Licensor than provided for herein.

License Property
Licensed Patent Rights, as used herein, shall mean U.S. Patent Application Serial No. 08/151,065 and any other patent applications or patents covering Licensed Materials.  The term Licensed Patent Rights shall include any divisions, continuations, continuation-in-part or reissues, and all foreign counterparts thereof, covering Licensed Materials.

Licensed Materials, as used herein, shall mean cell lines that inducibly express adeno-associated virus (AAV) proteins developed by James P. Trempe, Ph.D., Biochemistry & Molecular Biology, MCO (hereinafter referred to as Investigator), and improvements made by Investigator to such cell lines which exist as of the date of execution of this Agreement or are conceived of and reduced to practice by Investigator during the five (5) year period beginning on the effective date of this Agreement and are owned by Licensor.

Licensed Product(s), as used herein, shall mean any composition of matter, product, apparatus, kit or component part thereof, and any process, procedure or method which cannot be developed, manufactured, used or sold without utilizing Licensed Rights.

Field of Use
This agreement pertains to the medical industry relating to Cell Lines.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.